Articles written by: Bernard Talley

180 Degree Capital Corp. (TURN)’s Financial Results Comparing With Eagle Point Credit Company Inc. (NYSE:ECCA)

Both 180 Degree Capital Corp. (NASDAQ:TURN) and Eagle Point Credit Company Inc. (NYSE:ECCA) are each other’s competitor in the Asset Management industry. Thus the compare of their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation. Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings […]

Reviewing Hepion Pharmaceuticals Inc. (HEPA)’s and GlycoMimetics Inc. (NASDAQ:GLYC)’s results

Both Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) and GlycoMimetics Inc. (NASDAQ:GLYC) are Biotechnology companies, competing one another. We will compare their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation. Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hepion Pharmaceuticals Inc. 3 0.00 N/A -86.02 […]

Comparison of Torchlight Energy Resources Inc. (TRCH) and Pioneer Energy Services Corp. (NYSE:PES)

As Oil & Gas Drilling & Exploration businesses, Torchlight Energy Resources Inc. (NASDAQ:TRCH) and Pioneer Energy Services Corp. (NYSE:PES), are affected by contrast. This especially applies to their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation. Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share […]

As Ventas  (VTR) Valuation Rose, Shareholder Cohen & Steers Has Decreased Its Position; Genworth Finl (GNW) Market Valuation Rose While Alpine Associates Management Has Lifted by $1.71 Million Its Stake

As Ventas (VTR) Valuation Rose, Shareholder Cohen & Steers Has Decreased Its Position; Genworth Finl (GNW) Market Valuation Rose While Alpine Associates Management Has Lifted by $1.71 Million Its Stake

Alpine Associates Management Inc increased its stake in Genworth Finl Inc (GNW) by 31.39% based on its latest 2019Q2 regulatory filing with the SEC. Alpine Associates Management Inc bought 571,431 shares as the company’s stock rose 4.72% . The hedge fund held 2.39M shares of the life insurance company at […]

Comparing of CTI BioPharma Corp. (CTIC) and Dermira Inc. (NASDAQ:DERM)

CTI BioPharma Corp. (NASDAQ:CTIC) and Dermira Inc. (NASDAQ:DERM), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation of the two firms. Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings […]

Comparing of Aileron Therapeutics Inc. (ALRN) and CytRx Corporation (OTCMKTS:CYTR)

Aileron Therapeutics Inc. (NASDAQ:ALRN) and CytRx Corporation (OTCMKTS:CYTR), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations of the two firms. Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings […]

Holder Berkshire Asset Management Has Lifted Intel (INTC) Stake; Valley National Advisers Has Lowered Coca Cola Co (KO) Stake by $1.45 Million as Shares Rose

Holder Berkshire Asset Management Has Lifted Intel (INTC) Stake; Valley National Advisers Has Lowered Coca Cola Co (KO) Stake by $1.45 Million as Shares Rose

Valley National Advisers Inc decreased its stake in Coca Cola Co (KO) by 86.19% based on its latest 2019Q2 regulatory filing with the SEC. Valley National Advisers Inc sold 28,969 shares as the company’s stock rose 8.31% . The institutional investor held 4,643 shares of the beverages (production and distribution) […]

Contrasting of Pluristem Therapeutics Inc. (PSTI) and Cyanotech Corporation (NASDAQ:CYAN)

As Biotechnology businesses, Pluristem Therapeutics Inc. (NASDAQ:PSTI) and Cyanotech Corporation (NASDAQ:CYAN), are affected by compare. This especially applies to their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation. Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pluristem Therapeutics Inc. 2 1200.88 N/A […]